3-(alpha-D-galactopyranosyloxy)-N-(3-{4-[3-({2-[(3-{4-[3-({[3-(hexopyranosyloxy)-5-nitrophenyl]carbonyl}amino)propyl]piperazin-1-yl}propyl)amino]-3,4-dioxocyclobut-1-en-1-yl}amino)propyl]piperazin-1-yl}propyl)-5-nitrobenzamide

DB04210ExperimentalSmall molecule

3-(alpha-D-galactopyranosyloxy)-N-(3-{4-[3-({2-[(3-{4-[3-({[3-(hexopyranosyloxy)-5-nitrophenyl]carbonyl}amino)propyl]piperazin-1-yl}propyl)amino]-3,4-dioxocyclobut-1-en-1-yl}amino)propyl]piperazin-1-yl}propyl)-5-nitrobenzamide: Overview.

Formula / weight: C₅₀H₇₂N₁₀O₂₀ · 1133.1617 g/mol (avg)

Resolves to

Compound

PubChem131704269

Structure

InChIKeyWWGXKLSKKKQRMN-MLHPNDMTSA-NSMILES

OCC1OC(OC2=CC(=CC(=C2)[N+]([O-])=O)C(=O)NCCCN2CCN(CCCNC3=C(NCCCN4CCN(CCCNC(=O)C5=CC(=CC(O[C@H]6O[C@H](CO)[C@H](O)[C@H](O)[C@H]6O)=C5)[N+]([O-])=O)CC4)C(=O)C3=O)CC2)C(O)C(O)C1O

Targets

P01556ctxB

What you can answer from here — as of September 24, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with 3-(alpha-D-galactopyranosyloxy)-N-(3-{4-[3-({2-[(3-{4-[3-({[3-(hexopyranosyloxy)-5-nitrophenyl]carbonyl}amino)propyl]piperazin-1-yl}propyl)amino]-3,4-dioxocyclobut-1-en-1-yl}amino)propyl]piperazin-1-yl}propyl)-5-nitrobenzamide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account